$TVTX vs $VERA: The Business That Already Exists vs the Upside That Could Become Enormous

1 · First principle: this is not really “FILSPARI versus TRUTAKNA”

The easiest way to misunderstand this comparison is to start with the question: which drug is better? It is a seductive question and probably less useful than it appears.

FILSPARI and TRUTAKNA are not two copies of the same product fighting to occupy an identical therapeutic slot. They intervene at different levels of disease biology. FILSPARI, or sparsentan, is a dual endothelin type A and angiotensin II type 1 receptor antagonist. Its role is to act directly on glomerular hemodynamics and pathways associated with proteinuria and progressive kidney injury. It is oral, once daily and non-immunosuppressive.

TRUTAKNA, atacicept-vymj, works further upstream. It is a fusion protein that blocks both BAFF and APRIL, two cytokines involved in B-cell survival, differentiation and production of abnormal IgA and autoantibodies implicated in IgAN biology. It is therefore an immune-directed therapy aimed at one of the biological sources of disease rather than only its downstream renal consequences. It is delivered once weekly through a subcutaneous autoinjector.

That distinction matters because the IgAN market may not become a contest where one winner eliminates every alternative. IgA nephropathy is moving toward multimodal management: foundational supportive care, hemodynamic control, SGLT2 inhibition, endothelin-pathway therapy, complement inhibition and treatments targeting B cells, APRIL or BAFF can potentially occupy different layers of the same therapeutic strategy.

That is where TVTX and VERA become very different investments. Travere has already demonstrated that it can obtain approval, convert accelerated approval into full approval, build a commercial franchise and extend that franchise into a second disease.

Vera instead offers an immunology platform with potentially broader biological reach, a much lower market valuation and a large amount of value that is still unproven: launch revenue, eGFR confirmation, full approval, expansion into additional diseases and the ability to compete commercially against much larger pharmaceutical companies.

2 · Is the IgAN market large enough for two winners? Probably. Five winners? That is the real question.

IgA nephropathy is no longer a niche kidney disease with one specialist drug. It has become one of the most competitive areas in modern nephrology.

Travere now describes the combined U.S. FILSPARI opportunity across IgAN and FSGS as exceeding 100,000 addressable patients. Within that broader franchise opportunity, the company estimates more than 30,000 addressable FSGS patients in the population relevant to the newer indication.

Vera, meanwhile, uses an estimate of roughly 160,000 diagnosed IgAN patients in the United States, with a meaningful portion commercially insured.

Those numbers are not interchangeable. They should not be added, subtracted or treated as direct epidemiological equivalents. “Diagnosed population,” “addressable population” and a population compatible with a specific FDA label describe different things.

The challenge for shareholders is that almost everyone now wants a piece of this market. FILSPARI is not competing only with TRUTAKNA. Novartis has Vanrafia, a selective ETA antagonist, and Fabhalta, a complement factor B inhibitor. Otsuka has VOYXACT, an anti-APRIL antibody already approved. Vertex may arrive by November with povetacicept, another dual BAFF/APRIL therapy and therefore the most direct mechanistic competitor to TRUTAKNA.

This produces an unusual commercial setup: the theoretical IgAN market is getting larger at the same time that the available revenue pool is becoming more fragmented. It is not enough to multiply 160,000 patients by an annual list price. Investors need to think about how many patients will actually qualify for advanced therapy, how nephrologists sequence multiple mechanisms, whether payers allow expensive combinations, and how quickly new entrants can take share from established products.

3 · FILSPARI: Travere already owns what Vera still has to prove — a commercial engine

TVTX’s simplest advantage is also one of the hardest things for a biotech to replicate: FILSPARI already sells.

Travere generated $169.6 million of total revenue in Q2 2026. U.S. net product sales reached $161.4 million, and FILSPARI alone contributed $141.1 million, up 96% from Q2 2025. During the first six months of 2026, FILSPARI generated $246.2 million, up 93% year over year.

Those are not yet global-pharma numbers, but they fundamentally change the financial profile. FILSPARI has crossed from regulatory asset to commercial franchise. Full-year 2025 U.S. net sales were $322 million. Q4 2025 reached $103.3 million, Q1 2026 reached $105.2 million and Q2 2026 accelerated to $141.1 million.

The commercial funnel may be even more interesting. Travere reported 908 Patient Start Forms in Q4 2025, 993 in Q1 2026 and 2,012 in Q2. The jump coincides with the April FSGS launch. It should therefore not be read as a pure acceleration of the existing IgAN business, but it does show that Travere’s commercial organization translated a new indication into immediate demand.

This matters because commercial infrastructure is often underestimated when investors compare a proven commercial-stage biotech with a newly approved company. TVTX already has nephrologist relationships, patient-support infrastructure, market-access experience, payer workflows, REMS familiarity and a proven process for turning prescriptions into reimbursed treatment.

VERA has recruited experienced commercial executives and built launch infrastructure, but the company itself does not yet possess the same operating track record.

4 · FILSPARI’s second life: FSGS is the real reason TVTX is different from VERA

If FILSPARI were only another IgAN drug entering an increasingly crowded market, Travere’s near-$6 billion valuation would be much harder to defend. The April 13, 2026 FSGS approval changes that equation.

The FDA approved FILSPARI to reduce proteinuria in adults and pediatric patients aged eight years and older with FSGS without nephrotic syndrome. As of August 19, 2026, it is the first and only medicine specifically approved by the FDA for FSGS.

The label does not cover every FSGS patient. The “without nephrotic syndrome” limitation is important and prevents investors from converting the entire epidemiological FSGS population into an immediately addressable market. Travere nevertheless estimates more than 30,000 U.S. patients within its addressable FSGS opportunity.

In the DUPLEX population without nephrotic syndrome, FILSPARI produced a 48% reduction in proteinuria from baseline through Week 108 versus 27% with irbesartan, together with a numerical kidney-function benefit.

This may be the single most important distinction between the two equities. Vera today remains overwhelmingly dependent on TRUTAKNA’s regulatory and commercial performance in IgAN. Travere has a bifurcated renal franchise: a highly competitive IgAN market and a much less served FSGS market.

That does not guarantee a permanent monopoly. Novartis and other developers are exploring therapies in FSGS, while Vera itself is evaluating atacicept in immune-defined FSGS/MCD populations through PIONEER. But entering first into a disease with no prior FDA-approved medicine can create physician familiarity, real-world evidence and prescribing inertia that competitors may need time to overcome.

5 · TRUTAKNA: the VERA thesis starts further upstream in disease biology

If TVTX owns the commercial-maturity advantage, VERA’s attraction starts with atacicept biology.

TRUTAKNA binds BAFF and APRIL. Those cytokines are involved in B-cell survival and maturation and in immunoglobulin production. IgAN disease biology involves production of galactose-deficient IgA1, generation of autoantibodies and formation of immune complexes that eventually deposit in the kidney. Blocking both BAFF and APRIL attempts to intervene at a source of the immunological disease process rather than focusing exclusively on downstream glomerular injury.

That is why Vera describes TRUTAKNA as potentially foundational. “Foundational” remains a company positioning term rather than a definitive conclusion about future treatment sequencing, but the strategic concept is understandable: if atacicept produces durable preservation of kidney function in addition to reducing proteinuria, it could become a therapy that physicians build around rather than simply one more antiproteinuric option.

The July 7, 2026 accelerated approval is based on the prespecified ORIGIN 3 interim analysis. Among the first 203 evaluable patients at Week 36, TRUTAKNA produced a 46% reduction in proteinuria from baseline and a 42% reduction relative to placebo, with p<0.0001.

The drug also reduced Gd-IgA1 by 68%, and Vera reported hematuria resolution in 81% of patients who had hematuria at baseline. Those secondary measures strengthen the biological coherence of the result: the trial is not showing only less protein in the urine, but also biomarker changes consistent with the intended immune mechanism.

That is exactly what the market is waiting to learn in Q3 2026.

6 · Clinical data: the cross-trial comparison that does not work

A social-media graphic could put “FILSPARI -49.8% proteinuria” beside “TRUTAKNA -46% proteinuria” and declare that TVTX wins 49.8 to 46. That would be scientifically weak.

PROTECT and ORIGIN 3 are different studies. FILSPARI was tested against high-dose irbesartan, an active comparator with real antiproteinuric activity. TRUTAKNA was tested against placebo on top of protocol-defined background therapy. The populations, eligibility criteria, timing and statistical frameworks also differ.

Where FILSPARI has an unquestionable advantage today is maturity of kidney-function evidence. In the dataset supporting full IgAN approval, mean eGFR slope from baseline through Week 110 was approximately -3.0 mL/min/1.73m²/year with FILSPARI versus -4.2 with irbesartan, for a treatment effect of roughly 1.2 in the modified ITT framework reflected in the regulatory package.

TRUTAKNA does not yet have the same degree of confirmatory kidney-function validation. Its accelerated approval is based on proteinuria, and continued approval depends on verification of clinical benefit.

That makes ORIGIN 3 eGFR the next major inflection point for VERA. A strong result dramatically narrows the regulatory and evidentiary gap between the two assets. A weak or ambiguous result would pressure the thesis that upstream immune targeting can deliver durable disease modification.

7 · Safety and convenience: oral does not automatically mean easier, injection does not automatically mean worse

From a convenience perspective, FILSPARI has an intuitive advantage: one oral tablet every day. TRUTAKNA is a once-weekly subcutaneous injection delivered through a home autoinjector.

But real-world commercial convenience does not stop at route of administration.

FILSPARI carries a boxed warning related to hepatotoxicity and embryo-fetal toxicity. It is distributed under a REMS framework related to liver risk, and liver testing is required before treatment and periodically during therapy. Other clinically relevant risks include hypotension, hyperkalemia, acute kidney injury and fluid retention. Because sparsentan includes AT1 receptor activity, it is not simply layered on top of incompatible renin-angiotensin therapies as though it were mechanistically independent.

TRUTAKNA does not carry an equivalent REMS structure, but its mechanism alters B-cell-related signaling and therefore requires attention to infection risk and immunoglobulin effects. Vera reported infections in 32% of TRUTAKNA patients versus 28% of placebo patients in the relevant clinical dataset.

There is therefore no universal answer from the nephrologist’s point of view. One patient may strongly prefer a tablet. Another may find a weekly injection simple. A patient with hepatic risk may be a less attractive FILSPARI candidate, while a patient with recurrent infections may require more caution with an immune-directed therapy.

That is another reason the category can support multiple products instead of one universal winner.

8 · The chart that really separates the companies: revenue versus spending

The contrast is hard to miss. TVTX is now a company in which the lead product finances a meaningful portion of the organization. Travere reported approximately $4.0 million of GAAP operating income in Q2 before financing and other non-operating items. The roughly $34.8 million net loss was heavily affected by a $40 million charge tied to repurchase/induced conversion activity involving the 2029 convertible notes.

Vera, by contrast, is in the most expensive stage of its transformation. It still has to fund ORIGIN, PIONEER and broader R&D while simultaneously building sales, market access, patient support, medical affairs and launch infrastructure. Q2 G&A increased to $52.4 million from $21.9 million a year earlier, largely because TRUTAKNA launch preparation was already underway.

That is exactly what should happen when a development-stage biotech becomes commercial. But it means the next several quarters must answer a question TVTX has already answered: how quickly can product revenue begin absorbing the new cost base?

9 · Balance sheet: VERA carries less debt; TVTX has far more ability to self-fund

If we look only at June 30 liquidity, the two companies appeared almost identical: $489.2 million for Travere and $499.2 million for Vera.

That is an incomplete snapshot.

Travere subsequently paid $112.5 million in cash to Everest Medicines in July as the upfront payment for civorebrutinib rights. That means the June balance should not be described as if it remained untouched after quarter-end.

Vera also incurred post-approval obligations toward Ares Trading after TRUTAKNA’s accelerated approval. Again, June 30 liquidity should not be presented as a current cash balance.

On leverage, however, Vera has the cleaner balance sheet. Travere carried $602.8 million of convertible debt at June 30 after issuing $525 million of 0.50% convertible senior notes due 2032 and repurchasing a significant portion of its previous 2029 notes.

Vera had only $75 million of term debt actually drawn. Its Oxford facility does provide additional capacity that may be used later.

So VERA is less levered, but its cash burn is much heavier. During the first six months of 2026, Vera used approximately $206.8 million of operating cash and recorded a net loss above $200 million. Travere is far closer to self-funding its operating organization because FILSPARI revenue is already scaling.

TVTX has more debt. VERA has more urgency to turn sales into cash flow.

10 · Valuation: TVTX costs roughly 2.6 times VERA. But investors are not buying the same thing.

Why pay almost $6 billion for Travere when Vera is valued at only a little more than $2.3 billion?

Because the Travere valuation buys a company that has already demonstrated demand, reimbursement, growth, full IgAN approval and an FSGS expansion. Vera’s valuation largely represents expected future value from TRUTAKNA and potential future indications.

A simple exercise illustrates the difference. If we mechanically annualized FILSPARI’s $141.1 million Q2 sales — which is not a forecast — the implied run-rate would be roughly $564 million. TVTX’s market capitalization would therefore sit at a little over 10 times that annualized FILSPARI run-rate. That is not cheap, but the denominator can expand quickly if FSGS continues scaling.

VERA does not yet have a meaningful sales multiple. Approval arrived only on July 7, and Vera itself expects the earliest launch quarters to remain small relative to the long-term opportunity. The roughly $2.33 billion market cap is therefore mostly a vote on the future.

11 · Analyst targets: Wall Street sees more upside in VERA, but dispersion reveals the real risk

Analyst price targets are useful only when read for what they are: outputs of valuation models built on assumptions about commercial penetration, net pricing, regulatory probability, patent duration, cost of capital and pipeline value. They are not guarantees and they are not Merlintrader fair value estimates.

To keep the headline comparison methodologically consistent, we use the same consensus aggregator for both companies. On August 19, Investing.com showed an average 12-month target of approximately $72.79 for TVTX and $77.14 for VERA. Against the intraday prices used in this report, that translates into theoretical upside of roughly 14% for TVTX and 138% for VERA.

That is an enormous difference. It does not mean Wall Street believes VERA has a dramatically higher probability of success. Much of that apparent upside exists because VERA trades far below many bullish models after the stock’s correction, while launch execution, confirmatory eGFR and future BAFF/APRIL competition remain highly uncertain.

12 · TRUTAKNA at roughly $425,000 per year: enormous potential, but list price is not revenue

TRUTAKNA launched with a reported wholesale acquisition cost of approximately $425,000 per year, equivalent to about $32,700 for a 28-day supply. That is a list price, not the net revenue Vera will receive after rebates, discounts, copay assistance and other gross-to-net items.

The number becomes eye-catching when multiplied by Vera’s estimate of roughly 160,000 diagnosed U.S. IgAN patients.

160,000 × $425,000 = $68 billion. Obviously that is not a credible revenue forecast for Vera.

Not every patient is eligible, not every patient requires advanced therapy, not every patient will obtain reimbursement, net price will be below WAC and there are multiple competing products.

A more useful way to understand the asymmetry is to ask how many annualized patients are required for TRUTAKNA to become a financially meaningful product at list-price-equivalent economics.

The point is not to forecast $4 billion. The point is that VERA does not need to capture an enormous percentage of diagnosed IgAN patients to generate substantial revenue.

The other side of that equation is payer pressure. A high-priced biologic entering a market with several mechanisms may face prior authorization, step therapy, combination restrictions and increasingly sophisticated payer segmentation.

If nephrologists ultimately want to use a kidney-targeted drug, an SGLT2 inhibitor and a BAFF/APRIL therapy together in selected patients, the total treatment cost can become significant. Strong clinical value may justify combination treatment; payers may still demand tighter patient selection.

13 · Royalties: neither TVTX nor VERA keeps 100% of the value of its potential blockbuster

Another common biotechnology-modeling mistake is to take peak sales and treat them as though almost all of the economics flow directly to the listed company.

FILSPARI is derived from a licensing arrangement, and Travere owes escalating royalties broadly in the 15%–17% range on sparsentan net sales. That represents a permanent economic burden on the franchise.

Vera retains worldwide rights to atacicept, but TRUTAKNA was originally licensed from Ares Trading, an affiliate of Merck KGaA. Vera owes tiered royalties in the low-double-digit through mid-teens range on annual net sales, in addition to regulatory and commercial milestones.

This gives Vera a form of optionality that may not be fully reflected in its current market value. If TRUTAKNA becomes a major global therapy, Vera controls the commercialization economics more directly.

Travere has chosen a more asset-light model outside the United States. International partners can generate meaningful milestones and royalties while reducing Travere’s own commercialization cost, execution risk and need to build global sales organizations.

That reduces direct upside on every dollar of international sales, but it also makes the business less capital intensive.

14 · Intellectual property: the market looks toward 2037 for TVTX and beyond 2040 for VERA — but the details matter

Once a biotechnology company is valued in the billions, “how long does the patent last?” becomes almost as important as “how much does the product sell?”

In May 2026, Travere received a Notice of Allowance from the USPTO for a patent application covering certain methods of using FILSPARI in IgAN. Once issued, the patent is expected to provide coverage for specified methods of use through October 2037, and Travere intends to seek Orange Book listing.

The phrase “once issued” matters. A Notice of Allowance is an advanced stage of the patent process, but it is not identical to saying that every competitive barrier through 2037 is already permanent and unchallengeable.

Vera has a different IP profile. Parts of atacicept’s older patent estate have nearer expiration dates, but Vera controls newer applications directed specifically to IgAN and other autoimmune glomerular diseases that could extend relevant protection well beyond 2040 if issued.

On a long horizon, Vera’s potential window is therefore attractive. But Ares royalties and license economics continue to apply even if the patent moat proves durable.

15 · Pipeline: Travere is more diversified today; Vera could become much more diversified tomorrow

Pipeline analysis is another area where a superficial read can reverse the conclusion.

TVTX initially looks like a “FILSPARI company.” In reality it now has three distinct strategic pillars.

TVTX · Pegtibatinase

Pegtibatinase, TVT-058, is in Phase 3 HARMONY for classical homocystinuria. The pivotal study is expected to enroll roughly 70 patients, and Travere guides to topline data in the second half of 2027. If successful, pegtibatinase could become the first disease-modifying therapy specifically developed for HCU.

That matters strategically because it moves TVTX outside pure nephrology and creates a second rare-disease franchise with very different commercial dynamics from FILSPARI.

TVTX · Civorebrutinib

Licensing civorebrutinib/EVER001 from Everest added another layer. Civorebrutinib is an oral reversible covalent BTK inhibitor that Travere intends to explore in primary membranous nephropathy, immune-mediated FSGS and minimal change disease.

The concept is particularly interesting because it creates internal strategic complementarity. FILSPARI protects the glomerulus through a kidney-targeted mechanism; civorebrutinib may address an immune driver in selected patients. Travere can therefore participate in the same multimodal treatment evolution that creates competitive pressure on FILSPARI in IgAN.

VERA · PIONEER

Vera’s real optionality is tied to whether BAFF/APRIL inhibition works outside IgAN. PIONEER is exploring atacicept in primary membranous nephropathy and in selected FSGS/MCD populations identified through immune markers such as anti-nephrin autoantibodies.

If those cohorts produce compelling signals, VERA stops being “TRUTAKNA for IgAN” and becomes a renal-immunology company with one asset capable of expanding across multiple diseases.

VERA · VT-109 and MAU868

VT-109 is a next-generation BAFF/APRIL fusion protein at an early stage, while MAU868 is an antibody against BK virus with prior clinical experience. At this point, neither deserves to dominate the valuation. They represent optionality rather than established pillars equivalent to FILSPARI or TRUTAKNA.

16 · The elephant in VERA’s room is called Vertex

Any bullish Vera analysis that ignores povetacicept is incomplete.

Vertex has an FDA-accepted BLA seeking accelerated approval of povetacicept in IgAN. The PDUFA date is November 30, 2026.

And povetacicept is not a distant competitor mechanistically. It is also a dual BAFF/APRIL inhibitor.

In Phase 3 RAINIER, a global placebo-controlled trial in 605 adults, the Week 36 interim analysis showed a 52.0% reduction in proteinuria from baseline and a 49.8% reduction relative to placebo, with p<0.0001, alongside a 77.4% reduction in serum Gd-IgA1. Dosing in that trial is 80 mg subcutaneously every four weeks, against TRUTAKNA’s weekly injection — a difference that belongs in any commercial comparison, because convenience is one of the few levers a first mover can defend.

Again, that does not prove that povetacicept is superior to TRUTAKNA because there is no head-to-head trial. It is more than enough, however, to show that Vera will not own the dual BAFF/APRIL segment by itself.

Vertex also has financial scale, payer leverage and a commercial organization Vera cannot reproduce. If povetacicept receives approval with a competitive label, the commercial question becomes immediate: can TRUTAKNA’s first-mover period create enough prescribing inertia before Vertex arrives?

That is probably VERA’s most important competitive risk over the next year.

17 · TVTX is not protected either: Novartis, Otsuka and combination therapy can pressure IgAN growth

Travere faces its own competitive war. Novartis’s Vanrafia is the closest pharmacological comparison because it selectively blocks endothelin A signaling. Phase 3 ALIGN showed meaningful proteinuria reduction versus placebo, followed by kidney-function data supporting a slowing of disease progression.

Fabhalta acts through the alternative complement pathway and received traditional FDA approval in IgAN in July 2026. Novartis reported an approximately 48% slowing of eGFR decline relative to placebo over two years.

Otsuka’s VOYXACT, an anti-APRIL therapy, is already commercially available and now has follow-up kidney-function data that increase competitive pressure across the category.

In other words, FILSPARI cannot keep growing simply because it is approved. It must preserve a clearly defined place inside a new therapeutic architecture.

The biggest competitive threat is not necessarily that one new drug replaces FILSPARI in every patient. It is that FILSPARI receives a smaller portion of a treatment portfolio as more mechanisms become available.

That is why FSGS matters so much. It gives Travere a second growth market that is far less congested.

18 · Management: TVTX has already passed the commercial exam; VERA is about to sit it

Travere is led by Eric Dube. Over the last several years, management has navigated a difficult sequence: FILSPARI accelerated approval, uncertainty around confirmatory data, conversion to full IgAN approval, an evolving FSGS regulatory path and finally FSGS approval in April 2026.

What matters is not praising management. What matters is the operating result: FILSPARI moved from an approval-stage asset into a product producing more than $100 million per quarter, with sustained growth and a second approved indication.

Vera is led by founder Marshall Fordyce. The team has executed well on the clinical and regulatory side: ORIGIN 2b, ORIGIN 3, Breakthrough Therapy Designation, BLA submission, accelerated approval and an agreement with FDA that moved the confirmatory eGFR analysis from 2027 into Q3 2026.

Now the company enters a completely different territory.

Before TRUTAKNA, Vera had never commercialized a product. That is not criticism; it is simply the reality of a first launch.

The company has built sales, marketing, market access, patient support and medical-affairs capabilities and launched TRU SUPPORT to facilitate access.

But until investors see prescriptions, treated patients, gross-to-net economics and persistence, commercial execution remains something to prove rather than something the company has already demonstrated.

19 · Dilution: both companies have used the capital markets, but in different ways

Travere had more than 94 million common shares outstanding by June 2026, up from year-end 2025. It has also relied on convertible debt. Convertibles are not immediate share dilution, but they can become equity or create an overhang depending on share price and note terms.

Vera has relied more directly on equity. In December 2025 it issued more than 7 million new shares at $42.50, raising roughly $281 million net. By late July 2026, shares outstanding were just above 72 million.

That financing gave Vera the resources to launch from a position of strength, but it also highlights a basic truth: Vera may need more capital if TRUTAKNA does not reach meaningful commercial scale quickly enough.

Travere is further along that curve. Its operating business can increasingly support R&D and SG&A, although the convertible notes need to be included in any serious per-share valuation.

That is why a simplistic “cash per share” comparison is misleading. VERA has a cleaner leverage profile today but a heavy burn. TVTX carries more financial leverage but has a commercial engine that can reduce future financing needs.

20 · The catalyst timeline: VERA clearly has more short-term explosiveness

For catalyst-oriented traders, VERA is clearly the more event-loaded name in the near term. Within months, it may receive both a powerful eGFR confirmation and a direct Vertex competitor.

TVTX is currently more of a quarterly execution story: PSFs, FILSPARI sales, FSGS growth, real-world data and pipeline progression.

21 · Merlintrader Scorecard: not mathematics, but a way to see where the risk sits

The following scorecard is intentionally subjective. It does not represent clinical data, statistical probabilities or a target price. Its purpose is to visualize the type of exposure an investor is taking.

22 · TVTX scenario analysis: what has to happen for $6 billion to look cheap three years from now?

Bull Case

FILSPARI maintains strong IgAN growth despite increasing competition, and FSGS develops into a substantial second commercial franchise. The two indications together push the product toward billion-dollar-scale revenue; international partners contribute royalties and milestones; civorebrutinib produces convincing data in pMN/FSGS/MCD; HARMONY is positive and pegtibatinase creates another independent rare-disease franchise.

Under that scenario, the convertible debt becomes manageable relative to enterprise value and cash generation.

The current market capitalization would not represent the destination. It would represent the entry price into a multi-franchise rare-disease company.

Base Case

FILSPARI continues growing, but IgAN becomes increasingly fragmented and most incremental upside comes from FSGS. Travere achieves more consistent operating profitability, while the next pipeline franchises remain several years away. TVTX becomes a good commercial biotech, but the already-high valuation limits multiple expansion.

Bear Case

New mechanisms reduce FILSPARI growth in IgAN; FSGS adoption is slower than expected; royalties, commercial investment, R&D and debt reduce free-cash-flow conversion; pegtibatinase fails or civorebrutinib does not differentiate.

In that scenario the risk is not necessarily that Travere becomes a “no-product biotech” again. The risk is that a good company was simply too expensive at the original purchase price.

23 · VERA scenario analysis: what has to happen for $2.3 billion to look tiny?

Bull Case

ORIGIN 3 eGFR shows convincing kidney-function preservation; Vera submits the sBLA in Q4 and achieves full approval in 2027. TRUTAKNA’s launch beats expectations, payer access is better than feared and high pricing allows meaningful revenue with relatively modest patient penetration.

PIONEER shows activity in additional autoimmune glomerulopathies and atacicept becomes a genuine pipeline-in-a-product. Vertex enters the market, but first-mover familiarity and TRUTAKNA prescribing experience allow Vera to maintain meaningful share. Under that scenario, a company valued around $2.3 billion can transform into a major renal-immunology franchise, and the operating leverage on equity value becomes enormous.

Base Case

eGFR is sufficient to maintain the path toward full approval, but the launch takes longer because of payer friction and growing competition. TRUTAKNA becomes a meaningful franchise but shares the market with VOYXACT and povetacicept. Vera continues funding R&D and commercialization and may need additional capital before becoming self-sustaining.

Bear Case

The eGFR analysis is disappointing or ambiguous; Vertex obtains povetacicept approval with a clinical or dosing profile perceived as more attractive; Otsuka strengthens its APRIL position; payers and nephrologists slow TRUTAKNA adoption; Vera continues consuming capital and returns to the equity market.

In that scenario, the lower market capitalization does not automatically protect shareholders. VERA remains highly concentrated around the success of a single franchise.

24 · Who might prefer TVTX and who might prefer VERA?

25 · The conclusion that does not fit in a tweet

TVTX and VERA can both become successful companies and still produce completely different outcomes for shareholders.

Travere is the easier investment to explain today. FILSPARI exists, sells, grows and has two indications. The company has already passed through stages that destroy many biotechnology stories: accelerated approval, confirmatory evidence, full approval, market access, commercial ramp and label expansion.

That increased certainty has a price. A market capitalization near $6 billion means investors are not buying a forgotten small-cap biotech. They are buying a company from which the market now expects continued growth. A weak FILSPARI quarter or slower FSGS adoption would not be treated as a minor deviation; it would directly change the valuation model.

The analyst-target picture makes the same point. Many recent TVTX targets cluster in the $70–85 zone. With the stock already above $63 in the snapshot used here, TVTX has consumed a significant portion of the upside Wall Street saw only months earlier. Continued share-price gains increasingly require actual operating estimates to move higher rather than merely a higher multiple.

Vera is almost the opposite.

A market capitalization around $2.3 billion leaves room for much more violent percentage expansion if TRUTAKNA becomes a multi-billion-dollar franchise. BAFF/APRIL biology is compelling, proteinuria data are strong and Gd-IgA1 reduction provides mechanistically coherent evidence.

But as of August 19, 2026, investors still have not seen two of the most important things: how much TRUTAKNA will actually sell and how well it preserves kidney function in the complete Phase 3 analysis.

That is why VERA analyst targets are so dispersed. Wedbush can sit near $34 while Cantor reaches $100. This is not simply disagreement about a drug price. It is disagreement over future market share, eGFR success, Vertex competitive pressure and Vera’s ability to build a global franchise.

There is also one detail that prevents the easy “next TVTX” narrative: Vertex may arrive on November 30 with another dual BAFF/APRIL product. If povetacicept is approved and physicians or payers prefer the Vertex product, Vera may be forced into a commercial war before its own franchise has fully formed.

Stripped to its two shortest descriptions, the comparison looks like this.

TVTX is currently the more de-risked quality story. It has commercial proof, FSGS and a much stronger ability to finance future growth internally.

VERA currently offers more convexity. Its market capitalization is much lower, and a strong eGFR result followed by a fast commercial ramp could force the market to revalue the company dramatically.

But that also means the decision depends heavily on the type of risk an investor wants to own.

An investor who fears clinical, regulatory and first-launch failure may find TVTX easier to underwrite. An investor who fears paying too much for growth already recognized by the market may find VERA more interesting.

VERA’s valuation, however, does not rest only on an already approved drug. It rests on whether Vera can become a commercial company before Vertex and other competitors redesign the market around it.

The answer to “which has more potential?” is therefore paradoxical but useful.

That is exactly the difference an investor should understand before deciding which company deserves further research or a place on a watchlist.

26 · What to monitor every quarter

More Merlintrader Research

Primary Sources, Market Data and Analyst Targets

This comparison relies primarily on SEC filings, FDA documents and official company communications. Cross-trial comparisons are deliberately limited because the studies use different designs and comparators. Analyst targets necessarily come from third-party market sources: company investor-relations pages usually identify the analysts covering the stock but do not publish their price targets.

• Travere Therapeutics · Q2 2026 Financial Results
  
  Revenue, FILSPARI sales, PSFs, liquidity, convertibles, pipeline and civorebrutinib
  
• Travere · FILSPARI full FDA approval in FSGS
  
  FSGS indication and addressable population
  
• Travere · FILSPARI full approval in IgAN
  
  PROTECT, proteinuria and eGFR
  
• Travere · USPTO Notice of Allowance
  
  Potential IgAN method-of-use coverage through October 2037
  
• Travere · Analyst Coverage
  
  Official list of research firms covering TVTX
  
• TVTX · Recent analyst ratings and targets
  
  Recent Citi, Evercore, Wedbush, TD Cowen, Guggenheim, Canaccord and other revisions
  
• TVTX · Consensus analyst target
  
  Third-party consensus used for the like-for-like headline comparison
  
• Vera Therapeutics · Q2 2026 update
  
  TRUTAKNA launch, ORIGIN 3, Q2 financials and upcoming catalysts
  
• Vera Therapeutics · Q2 2026 Form 10-Q
  
  Cash, burn, debt, Ares economics, capital needs and risk factors
  
• FDA · TRUTAKNA
  
  Accelerated approval, mechanism, ORIGIN and indication
  
• Vera · TRUTAKNA approval release
  
  Weekly dosing, autoinjector and company approval data
  
• TRUTAKNA · reported launch list price
  
  Reported WAC of $32,700 per 28 days / approximately $425,000 annualized
  
• Vera · ORIGIN 3 eGFR alignment
  
  Q3 2026 eGFR, Q4 sBLA and potential 2027 full approval
  
• Vera · Analyst Coverage
  
  Official list of firms covering VERA
  
• VERA · Analyst price targets
  
  Recent Cantor, H.C. Wainwright, TD Cowen, Guggenheim, Wedbush and other targets
  
• VERA · Consensus analyst target
  
  Third-party consensus used for the like-for-like headline comparison
  
• Goldman Sachs · updated VERA target
  
  Target reduced to $80 while maintaining Buy after Q2 and competitive developments
  
• Vertex · Povetacicept BLA
  
  November 30, 2026 PDUFA
  
• Vertex · RAINIER Phase 3
  
  Povetacicept Week 36 efficacy
  
• Otsuka · VOYXACT
  
  APRIL inhibitor approval in IgAN
  
• Novartis · Vanrafia Phase 3 ALIGN
  
  Proteinuria and eGFR
  
• Novartis · Fabhalta traditional IgAN approval
  
  Traditional approval and kidney-function data